Norepinephrine use in cardiogenic shock patients is associated with increased 30 day mortality.

ABSTRACT:

Aims

Norepinephrine is recommended as a first-line vasopressor agent in the haemodynamic stabilization of cardiogenic shock. The survival benefit of norepinephrine therapy has not been demonstrated in clinical practice, however. This study aimed to explore the relationship between norepinephrine use and outcomes in cardiogenic shock patients in real-world conditions.

Methods and results

We conducted a retrospective cohort study based on the Medical Information Mart for Intensive Care III (MIMIC-III) database. Cardiogenic shock patients were enrolled and categorized into a norepinephrine group or a non-norepinephrine group. Propensity score matching (PSM) was used to control for confounders. Cox proportional-hazards models and multivariable logistic regression were used to in

SUBMITTER: Lu X 

PROVIDER: S-EPMC9065839 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature